The state of New Jersey currently has 419 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including New Brunswick, Hackensack, Newark and Morristown.
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
Recruiting
The purpose of this study is to find out whether adding pembrolizumab, with or without olaparib, to standard radiation therapy is a safe and effective treatment for metastatic breast cancer, , and to see whether the study treatment is better than, the same as, or worse than the usual approach (radiation therapy alone).
Gender:
Female
Ages:
18 years and above
Trial Updated:
10/04/2023
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +2 locations
Conditions: Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer
L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
Recruiting
This study will evaluate the safety and tolerability of escalating doses of L-DOS47 in combination with doxorubicin, as well as preliminary anti-tumor activity in patients with previously treated advanced pancreatic cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/02/2023
Locations: Atlantic Health System, Morristown Medical Center, Morristown, New Jersey
Conditions: Pancreas Cancer
NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors
Recruiting
Pediatric cancer survivors are at an increased risk of excessive weight gain and reduced exercise behaviors with the potential for this risk to worsen over time. With over 80% of pediatric cancer patients living to adulthood, many pediatric cancer survivors experience long-term health consequences such as heart disease - the leading cause of death in this population. The purpose of this clinical research study is to teach parents/caregivers skills that will help prevent and reduce the problems... Read More
Gender:
All
Ages:
Between 5 years and 14 years
Trial Updated:
09/26/2023
Locations: Hackensack Meridian Health, Hackensack, New Jersey
Conditions: Obesity, Childhood, Cancer, Survivorship
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
Recruiting
This is a Phase 1, open-label, 2-part, multi-center study evaluating the safety, tolerability, PK, pharmacodynamics (PD), immunogenicity, and antitumor activity of CUE-102 intravenous (IV) monotherapy in HLA-A*0201 positive patients with WT1 positive recurrent/metastatic solid tumors who have failed conventional therapies.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/25/2023
Locations: Carol G. Simon Cancer Center - Morristown Medical Center, Morristown, New Jersey
Conditions: Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
Recruiting
This is a 3-arm study stratified by plasma ctDNA. Patients with residual TNBC disease after pre-operative therapy will be assigned to 1 of 3 Arms based on plasma ctDNA positivity and genomic marker(s).
Gender:
All
Ages:
18 years and above
Trial Updated:
09/22/2023
Locations: Summit Health, Berkeley Heights, New Jersey
Conditions: Breast Cancer, Triple Negative Breast Cancer
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
Recruiting
Uterine serous carcinoma (USC) accounts for up to 40% of endometrial cancer-related deaths. Patients with USC share many genomic and clinical characteristics with patients who has serous ovarian cancer. The objective of this study is to evaluate the efficacy of maintenance Niraparib regimen in patients with advanced or platinum sensitive recurrent uterine serous carcinoma. Additionally, the investigators aim to further describe the safety of this regimen. The investigators hypothesize that Nirap... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
09/20/2023
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: Endometrial Cancer, Papillary Serous Endometrial Carcinoma, Uterine Serous Carcinoma, Endometrial Carcinoma, Cancer of the Endometrium
Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer
Recruiting
To evaluate the safety and preliminary efficacy of Preoperative ChemoRadiation and FOLFOXIRI and to Escalate Complete Response for Rectal Cancer patients.Go through laboratory and medical tests to verify eligibility to enter the study, receive the experimental combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil) prior to surgery and undergo laboratory tests and study procedures on specified days during the study per... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/17/2023
Locations: RWJBarnabas Health - Monmouth Medical Center, Lakewood, New Jersey +4 locations
Conditions: Cancer of Rectum
Pilot Study of Stomach Cancer Early Detection and Prevention With Endoscopy
Recruiting
Screening esophagogastroduodenoscopy (EGD )provides three distinct opportunities to decrease gastric cancer (GC) morbidity and mortality. has potential to discover cancer in early stages before the onset of symptoms, leading to higher rates of survival. Second, premalignant lesions such as adenomatous polyps, intestinal metaplasia and dysplasia can be discovered and removed with local resection, akin to polypectomies during screening colonoscopies, preventing the development of cancer. Third, EG... Read More
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
09/16/2023
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey +1 locations
Conditions: Gastric Cancer
Abatacept in Immune Checkpoint Inhibitor Myocarditis
Recruiting
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/06/2023
Locations: Robert Wood Johnson University Hospital, New Brunswick, New Jersey
Conditions: Myocarditis Acute, Cancer
Using Urine Samples to Identify Lung Cancer
Recruiting
The researchers are doing this study to test the ability of an animal biosensor platform (ABP) to detect NSCLC. Participants in this study will either be diagnosed with NSCLC, suspected to have NSCLC, or have not been diagnosed or suspected to have NSCLC. The ABP test uses laboratory animals that are trained to detect (by smell) different chemicals in urine. Studies show that people with lung cancer have unique chemicals in their urine that are not present in people without lung cancer, and res... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
09/05/2023
Locations: Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey +2 locations
Conditions: Non Small Cell Lung Cancer
Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer
Recruiting
The purpose of this study is to find out if fluid rinsed from peoples' airways (bronchial washing samples) during routine surgery to remove (resect) their non-small cell lung cancer (NSCLC) tumors contains enough vesicles to do testing that may help the researchers learn more about their NSCLC.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/01/2023
Locations: Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey +2 locations
Conditions: Non-Small Cell Lung Cancer
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Recruiting
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/28/2023
Locations: Monmouth Medical Center, Long Branch, New Jersey +2 locations
Conditions: Previously Treated Non-Small Cell Lung Cancer